Most Read Articles
Roshini Claire Anthony, 6 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Yesterday
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Roshini Claire Anthony, 08 Jul 2020

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Long-term survival improving in haematologic cancers

14 Jun 2020
Trojan Horse for cancer cells

Like short-term trends, long-term survival in haematologic malignancies appear to be improving, a recent study has found. However, late mortality remains an issue of concern.

Accessing the Surveillance, Epidemiology, and End Results-9 database, researchers assessed the 10- and 20-year relative survival (RS) for patients with haematologic malignancies aged 15 and above. The boomerang method was used as an analytic tool.

The 10- and 20-year standardized RS for multiple myeloma patients jumped from 18.1 percent and 8.0 percent, respectively, in 2002–2006 to 34.9 percent and 19.3 percent in 2012–2016. For those aged 15–64 years, the increase in 10- and 20-year survival was 20.5 percent and 10.8 percent units, respectively.

Similarly, 10- and 20-year estimates for acute lymphoblastic leukaemia jumped from 13.0 percent and 5.6 percent to 29.0 percent and 16.5 percent, respectively. The same was true for acute myeloblastic leukaemia (10-year RS: 14.0 percent to 19.0 percent).

Patients with chronic lymphoid leukaemia saw a major increase in RS, with 10-year survival rate increasing by 9.3 percent units and 15-year survival jumping by 18.6 percent units. This effect was stronger for those aged 15–64 years but nevertheless remained present in younger and older groups.

Similar patterns of improvement were observed for chronic myeloid leukaemia and Hodgkin and non-Hodgkin lymphoma.

“Long-term survival is still low and no plateau in survival was observed for most conditions, suggesting that there may be continued late mortality, either from late effects of the disease or therapy,” the researchers pointed out. Further research to determine the aetiology of these issues and any changes over time in the causes of late mortality as well as to minimize therapeutic toxicity is needed to ensure optimal outcomes.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Yesterday
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Roshini Claire Anthony, 08 Jul 2020

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.